{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T12:44:14Z","timestamp":1791290654882,"version":"4.3.0"},"reference-count":31,"publisher":"American Association for Cancer Research (AACR)","issue":"23","content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2008,12,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Targeting the tyrosine kinase activity of Bcr-Abl is an attractive therapeutic strategy in chronic myeloid leukemia (CML) and in Bcr-Abl\u2013positive acute lymphoblastic leukemia. Whereas imatinib, a selective inhibitor of Bcr-Abl tyrosine kinase, is now used in frontline therapy for CML, second-generation inhibitors of Bcr-Abl tyrosine kinase such as nilotinib or dasatinib have been developed for the treatment of imatinib-resistant or imatinib-intolerant disease. In the current study, we generated nilotinib-resistant cell lines and investigated their mechanism of resistance. Overexpression of BCR-ABL and multidrug resistance gene (MDR-1) were found among the investigated mechanisms. We showed that nilotinib is a substrate of the multidrug resistance gene product, P-glycoprotein, using verapamil or PSC833 to block binding. Up-regulated expression of p53\/56 Lyn kinase, both at the mRNA and protein level, was found in one of the resistant cell lines and Lyn silencing by small interfering RNA restored sensitivity to nilotinib. Moreover, failure of nilotinib treatment was accompanied by an increase of Lyn mRNA expression in patients with resistant CML. Two Src kinase inhibitors (PP1 and PP2) partially removed resistance but did not significantly inhibit Bcr-Abl tyrosine kinase activity. In contrast, dasatinib, a dual Bcr-Abl and Src kinase inhibitor, inhibited the phosphorylation of both BCR-ABL and Lyn, and induced apoptosis of the Bcr-Abl cell line overexpressing p53\/56 Lyn. Such mechanisms of resistance are close to those observed in imatinib-resistant cell lines and emphasize the critical role of Lyn in nilotinib resistance. [Cancer Res 2008;68(23):9809\u201316]<\/jats:p>","DOI":"10.1158\/0008-5472.can-08-1008","type":"journal-article","created":{"date-parts":[[2008,12,1]],"date-time":"2008-12-01T03:38:24Z","timestamp":1228102704000},"page":"9809-9816","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":190,"title":["Evidence that Resistance to Nilotinib May Be Due to BCR-ABL, Pgp, or Src Kinase Overexpression"],"prefix":"10.1158","volume":"68","author":[{"given":"Franc\u0327ois-Xavier","family":"Mahon","sequence":"first","affiliation":[{"name":"1He\u0301matopoi\u0308e\u0300se Leuce\u0301mique et Cible The\u0301rapeutique, INSERM U876, Universite\u0301 Victor Se\u0301galen, Laboratoire d'he\u0301matologie CHU de Bordeaux, Bordeaux cedex, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandrine","family":"Hayette","sequence":"additional","affiliation":[{"name":"2Laboratoire d'He\u0301matologie et de Cytoge\u0301ne\u0301tique, Centre Hospitalier Lyon Sud, Pierre Be\u0301nite, France Hematology Department, Ho\u0302pital Edouard Herriot, Lyon cedex, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vale\u0301rie","family":"Lagarde","sequence":"additional","affiliation":[{"name":"1He\u0301matopoi\u0308e\u0300se Leuce\u0301mique et Cible The\u0301rapeutique, INSERM U876, Universite\u0301 Victor Se\u0301galen, Laboratoire d'he\u0301matologie CHU de Bordeaux, Bordeaux cedex, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francis","family":"Belloc","sequence":"additional","affiliation":[{"name":"1He\u0301matopoi\u0308e\u0300se Leuce\u0301mique et Cible The\u0301rapeutique, INSERM U876, Universite\u0301 Victor Se\u0301galen, Laboratoire d'he\u0301matologie CHU de Bordeaux, Bordeaux cedex, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Be\u0301atrice","family":"Turcq","sequence":"additional","affiliation":[{"name":"1He\u0301matopoi\u0308e\u0300se Leuce\u0301mique et Cible The\u0301rapeutique, INSERM U876, Universite\u0301 Victor Se\u0301galen, Laboratoire d'he\u0301matologie CHU de Bordeaux, Bordeaux cedex, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franck","family":"Nicolini","sequence":"additional","affiliation":[{"name":"2Laboratoire d'He\u0301matologie et de Cytoge\u0301ne\u0301tique, Centre Hospitalier Lyon Sud, Pierre Be\u0301nite, France Hematology Department, Ho\u0302pital Edouard Herriot, Lyon cedex, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Coralie","family":"Belanger","sequence":"additional","affiliation":[{"name":"3Novartis Pharma AG, Basel, Switzerland; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul W.","family":"Manley","sequence":"additional","affiliation":[{"name":"3Novartis Pharma AG, Basel, Switzerland; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ce\u0301dric","family":"Leroy","sequence":"additional","affiliation":[{"name":"4CNRS UMR5237, Centre de Recherche de Biochimie Macromole\u0301culaire, Montpellier, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriel","family":"Etienne","sequence":"additional","affiliation":[{"name":"1He\u0301matopoi\u0308e\u0300se Leuce\u0301mique et Cible The\u0301rapeutique, INSERM U876, Universite\u0301 Victor Se\u0301galen, Laboratoire d'he\u0301matologie CHU de Bordeaux, Bordeaux cedex, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serge","family":"Roche","sequence":"additional","affiliation":[{"name":"4CNRS UMR5237, Centre de Recherche de Biochimie Macromole\u0301culaire, Montpellier, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Max","family":"Pasquet","sequence":"additional","affiliation":[{"name":"1He\u0301matopoi\u0308e\u0300se Leuce\u0301mique et Cible The\u0301rapeutique, INSERM U876, Universite\u0301 Victor Se\u0301galen, Laboratoire d'he\u0301matologie CHU de Bordeaux, Bordeaux cedex, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2008,12,1]]},"reference":[{"key":"2022061700305682200_B1","doi-asserted-by":"crossref","unstructured":"Rowley JD, Testa JR. Chromosome abnormalities in malignant hematologic diseases. Adv Cancer Res\u20081982; 36: 103\u201348.","DOI":"10.1016\/S0065-230X(08)60423-6"},{"key":"2022061700305682200_B2","doi-asserted-by":"crossref","unstructured":"Groffen J, Heisterkamp N, Stam K. Oncogene activation by chromosomal translocation in chronic myelocytic leukemia. Cold Spring Harb Symp Quant Biol\u20081986; 51: 911\u201321.","DOI":"10.1101\/SQB.1986.051.01.104"},{"key":"2022061700305682200_B3","doi-asserted-by":"crossref","unstructured":"Melo JV. The diversity of BCR-ABL fusion proteins and their relationship to leukemia phenotype. Blood\u20081996; 88: 2375\u201384.","DOI":"10.1182\/blood.V88.7.2375.bloodjournal8872375"},{"key":"2022061700305682200_B4","doi-asserted-by":"crossref","unstructured":"Daley GQ, Van Etten RA, Baltimore D. Induction of chronic myelogenous leukemia in mice by the P210bcr\/abl gene of the Philadelphia chromosome. Science\u20081990; 247: 824\u201330.","DOI":"10.1126\/science.2406902"},{"key":"2022061700305682200_B5","doi-asserted-by":"crossref","unstructured":"Lugo TG, Pendergast AM, Muller AJ, Witte ON. Tyrosine kinase activity and transformation potency of bcr-abl oncogene products. Science\u20081990; 247: 1079\u201382.","DOI":"10.1126\/science.2408149"},{"key":"2022061700305682200_B6","doi-asserted-by":"crossref","unstructured":"Druker BJ, Tamura S, Buchdunger E, et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med\u20081996; 2: 561\u20136.","DOI":"10.1038\/nm0596-561"},{"key":"2022061700305682200_B7","doi-asserted-by":"crossref","unstructured":"Azam M, Latek RR, Daley GQ. Mechanisms of autoinhibition and STI-571\/imatinib resistance revealed by mutagenesis of BCR-ABL. Cell\u20082003; 112: 831\u201343.","DOI":"10.1016\/S0092-8674(03)00190-9"},{"key":"2022061700305682200_B8","doi-asserted-by":"crossref","unstructured":"Druker BJ. Imatinib and chronic myeloid leukemia: validating the promise of molecularly targeted therapy. Eur J Cancer\u20082002; 38: S70\u20136.","DOI":"10.1016\/S0959-8049(02)80606-2"},{"key":"2022061700305682200_B9","doi-asserted-by":"crossref","unstructured":"Burke JR. BMS-345541 is a highly selective inhibitor of I[kappa]B kinase that binds at an allosteric site of the enzyme and blocks NF-[kappa]B-dependent transcription in mice. J Biol Chem\u20082003; 278: 1450\u20136.","DOI":"10.1074\/jbc.M209677200"},{"key":"2022061700305682200_B10","doi-asserted-by":"crossref","unstructured":"Weisberg E, Manley PW, Breitenstein W, et al. Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell\u20082005; 7: 129\u201341.","DOI":"10.1016\/j.ccr.2005.01.007"},{"key":"2022061700305682200_B11","doi-asserted-by":"crossref","unstructured":"Mahon FX, Deininger MW, Schultheis B, et al. Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: diverse mechanisms of resistance. Blood\u20082000; 96: 1070\u20139.","DOI":"10.1182\/blood.V96.3.1070.015k17_1070_1079"},{"key":"2022061700305682200_B12","doi-asserted-by":"crossref","unstructured":"Kabarowski JH, Allen PB, Wiedemann LM. A temperature sensitive p210 BCR-ABL mutant defines the primary consequences of BCR-ABL tyrosine kinase expression in growth factor dependent cells. EMBO J\u20081994; 13: 5887\u201395.","DOI":"10.1002\/j.1460-2075.1994.tb06934.x"},{"key":"2022061700305682200_B13","doi-asserted-by":"crossref","unstructured":"Pasquet JM, Quek L, Pasquet S, et al. Evidence of a role for SHP-1 in platelet activation by the collagen receptor glycoprotein VI. J Biol Chem\u20082000; 275: 28526\u201331.","DOI":"10.1074\/jbc.M001531200"},{"key":"2022061700305682200_B14","doi-asserted-by":"crossref","unstructured":"Gabert J, Beillard E, van der Velden VH, et al. Standardization and quality control studies of \u2018real-time\u2019 quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia\u2014a Europe Against Cancer program. Leukemia\u20082003; 17: 2318\u201357.","DOI":"10.1038\/sj.leu.2403135"},{"key":"2022061700305682200_B15","doi-asserted-by":"crossref","unstructured":"Mahon FX, Belloc F, Lagarde V, et al. MDR1 gene overexpression confers resistance to imatinib mesylate in leukemia cell line models. Blood\u20082003; 101: 2368\u201373.","DOI":"10.1182\/blood.V101.6.2368"},{"key":"2022061700305682200_B16","doi-asserted-by":"crossref","unstructured":"Dai Y, Rahmani M, Corey SJ, Dent P, Grant S. A Bcr\/Abl-independent, Lyn-dependent form of imatinib mesylate (STI-571) resistance is associated with altered expression of Bcl-2. J Biol Chem\u20082004; 279: 34227\u201339.","DOI":"10.1074\/jbc.M402290200"},{"key":"2022061700305682200_B17","doi-asserted-by":"crossref","unstructured":"Daley GQ. Dodging the magic bullet: understanding imatinib resistance. Cancer Biol Ther\u20082003; 2: 109\u201310.","DOI":"10.4161\/cbt.287"},{"key":"2022061700305682200_B18","doi-asserted-by":"crossref","unstructured":"Deininger MW, Druker BJ. SRCircumventing imatinib resistance. Cancer Cell\u20082004; 6: 108\u201310.","DOI":"10.1016\/j.ccr.2004.08.006"},{"key":"2022061700305682200_B19","doi-asserted-by":"crossref","unstructured":"Campos L, Guyotat D, Archimbaud E, et al. Clinical significance of multidrug resistance P-glycoprotein expression on acute nonlymphoblastic leukemia cells at diagnosis. Blood\u20081992; 79: 473\u20136.","DOI":"10.1182\/blood.V79.2.473.bloodjournal792473"},{"key":"2022061700305682200_B20","doi-asserted-by":"crossref","unstructured":"Belloc F, Cotteret S, Labroille G, et al. Bcr-abl translocation can occur during the induction of multidrug resistance and confers apoptosis resistance on myeloid leukemic cell lines. Cell Death Differ\u20081997; 4: 806\u201314.","DOI":"10.1038\/sj.cdd.4400303"},{"key":"2022061700305682200_B21","doi-asserted-by":"crossref","unstructured":"Watanabe T, Tsuge H, Oh-Hara T, Naito M, Tsuruo T. Comparative study on reversal efficacy of SDZ PSC 833, cyclosporin A and verapamil on multidrug resistance in vitro and in vivo. Acta Oncol\u20081995; 34: 235\u201341.","DOI":"10.3109\/02841869509093961"},{"key":"2022061700305682200_B22","doi-asserted-by":"crossref","unstructured":"Morinaga K, Yamauchi T, Kimura S, Maekawa T, Ueda T. Overcoming imatinib resistance using Src inhibitor CGP76030, Abl inhibitor nilotinib and Abl\/Lyn inhibitor INNO-406 in newly established K562 variants with BCR-ABL gene amplification. Int J Cancer\u20082008; 122: 2621\u20137.","DOI":"10.1002\/ijc.23435"},{"key":"2022061700305682200_B23","doi-asserted-by":"crossref","unstructured":"Dulucq S, Bouchet S, Turcq B, et al. Multidrug resistance gene (MDR1) polymorphisms are associated with major molecular responses to standard-dose imatinib in chronic myeloid leukemia. Blood\u20082008; 112: 2024\u20137.","DOI":"10.1182\/blood-2008-03-147744"},{"key":"2022061700305682200_B24","doi-asserted-by":"crossref","unstructured":"Donato NJ, Wu JY, Stapley J, et al. BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571. Blood\u20082003; 101: 690\u20138.","DOI":"10.1182\/blood.V101.2.690"},{"key":"2022061700305682200_B25","doi-asserted-by":"crossref","unstructured":"Tatton L, Morley GM, Chopra R, Khwaja A. The Src-selective kinase inhibitor PP1 also inhibits Kit and Bcr-Abl tyrosine kinases. J Biol Chem\u20082003; 278: 4847\u201353.","DOI":"10.1074\/jbc.M209321200"},{"key":"2022061700305682200_B26","doi-asserted-by":"crossref","unstructured":"Grishin A, Sinha S, Roginskaya V, et al. Involvement of Shc and Cbl-PI 3-kinase in Lyn-dependent proliferative signaling pathways for G-CSF. Oncogene\u20082000; 19: 97\u2013105.","DOI":"10.1038\/sj.onc.1203254"},{"key":"2022061700305682200_B27","doi-asserted-by":"crossref","unstructured":"Sampson M, Zhu QS, Corey SJ. Src kinases in G-CSF receptor signaling. Front Biosci\u20082007; 12: 1463\u201374.","DOI":"10.2741\/2160"},{"key":"2022061700305682200_B28","doi-asserted-by":"crossref","unstructured":"Meyn MA, III, Wilson MB, Abdi FA, et al. Src family kinases phosphorylate the Bcr-Abl SH3-2 region and modulate Bcr-Abl transforming activity. J Biol Chem\u20082006; 281: 30907\u201316.","DOI":"10.1074\/jbc.M605902200"},{"key":"2022061700305682200_B29","doi-asserted-by":"crossref","unstructured":"Wu J, Meng F, Lu H, et al. Lyn regulates BCR-ABL and Gab2 tyrosine phosphorylation and c-Cbl protein stability in imatinib-resistant chronic myelogenous leukemia cells. Blood\u20082008; 111: 3821\u20139.","DOI":"10.1182\/blood-2007-08-109330"},{"key":"2022061700305682200_B30","doi-asserted-by":"crossref","unstructured":"Rix U, Hantschel O, Durnberger G, et al. Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib and dasatinib reveal novel kinase and non-kinase targets. Blood\u20082007; 110: 4055\u201363.","DOI":"10.1182\/blood-2007-07-102061"},{"key":"2022061700305682200_B31","doi-asserted-by":"crossref","unstructured":"Hantschel O, Rix U, Schmidt U, et al. The Btk tyrosine kinase is a major target of the Bcr-Abl inhibitor dasatinib. Proc Natl Acad Sci U S A\u20082007; 104: 13283\u20138.","DOI":"10.1073\/pnas.0702654104"}],"container-title":["Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/68\/23\/9809\/2594379\/9809.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/68\/23\/9809\/2594379\/9809.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,17]],"date-time":"2022-06-17T01:48:35Z","timestamp":1655430515000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerres\/article\/68\/23\/9809\/540919\/Evidence-that-Resistance-to-Nilotinib-May-Be-Due"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,12,1]]},"references-count":31,"journal-issue":{"issue":"23","published-online":{"date-parts":[[2008,12,1]]},"published-print":{"date-parts":[[2008,12,1]]}},"URL":"https:\/\/doi.org\/10.1158\/0008-5472.can-08-1008","relation":{"has-preprint":[{"id-type":"doi","id":"10.1158\/0008-5472.22375485.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.c.6497844","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22375482","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22375485","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.c.6497844.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22375482.v1","asserted-by":"object"}]},"ISSN":["0008-5472","1538-7445"],"issn-type":[{"value":"0008-5472","type":"print"},{"value":"1538-7445","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,12,1]]}}}